Skip to main content

Table 3 Dose modification protocol according to the level of adverse reaction caused by capecitabine therapy (Toxicity according to NCI CTC Version 3.0)

From: A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

Toxicity occurrence suggested measure dose during following cycle (% of original dose)
1   continue with current dose 100%
2 1st occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 100%
  2nd occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 75%
  3rd occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 50%
  4th occurrence final discontinuation of treatment -
3 1st occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 75%
  2nd occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 50%
  3rd occurrence final discontinuation of treatment -
4 1st occurrence final discontinuation of treatment or discontinuation till restitution to grade 0 or 1 toxicity 50%